Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/MECOM_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MECOM_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MECOM_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/MECOM_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MECOM_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MECOM_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MECOM_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/MECOM_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MECOM_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MECOM_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000632514 | Prostate | Tumor | chromatin organization | 104/3246 | 409/18723 | 2.02e-05 | 2.62e-04 | 104 |
GO:003109815 | Prostate | Tumor | stress-activated protein kinase signaling cascade | 68/3246 | 247/18723 | 4.03e-05 | 4.62e-04 | 68 |
GO:005140315 | Prostate | Tumor | stress-activated MAPK cascade | 66/3246 | 239/18723 | 4.69e-05 | 5.21e-04 | 66 |
GO:000647912 | Prostate | Tumor | protein methylation | 52/3246 | 181/18723 | 9.58e-05 | 9.35e-04 | 52 |
GO:000821312 | Prostate | Tumor | protein alkylation | 52/3246 | 181/18723 | 9.58e-05 | 9.35e-04 | 52 |
GO:003287215 | Prostate | Tumor | regulation of stress-activated MAPK cascade | 53/3246 | 192/18723 | 2.51e-04 | 2.11e-03 | 53 |
GO:001657112 | Prostate | Tumor | histone methylation | 41/3246 | 141/18723 | 3.79e-04 | 2.95e-03 | 41 |
GO:007030215 | Prostate | Tumor | regulation of stress-activated protein kinase signaling cascade | 53/3246 | 195/18723 | 3.80e-04 | 2.95e-03 | 53 |
GO:003287315 | Prostate | Tumor | negative regulation of stress-activated MAPK cascade | 19/3246 | 51/18723 | 5.52e-04 | 4.01e-03 | 19 |
GO:007030315 | Prostate | Tumor | negative regulation of stress-activated protein kinase signaling cascade | 19/3246 | 51/18723 | 5.52e-04 | 4.01e-03 | 19 |
GO:003496812 | Prostate | Tumor | histone lysine methylation | 34/3246 | 115/18723 | 8.31e-04 | 5.60e-03 | 34 |
GO:00616471 | Prostate | Tumor | histone H3-K9 modification | 16/3246 | 48/18723 | 5.39e-03 | 2.57e-02 | 16 |
GO:000725415 | Prostate | Tumor | JNK cascade | 42/3246 | 167/18723 | 6.68e-03 | 3.05e-02 | 42 |
GO:001802212 | Prostate | Tumor | peptidyl-lysine methylation | 34/3246 | 131/18723 | 8.36e-03 | 3.65e-02 | 34 |
GO:004632813 | Prostate | Tumor | regulation of JNK cascade | 34/3246 | 133/18723 | 1.06e-02 | 4.41e-02 | 34 |
GO:00328724 | Stomach | GC | regulation of stress-activated MAPK cascade | 26/1159 | 192/18723 | 1.40e-04 | 2.59e-03 | 26 |
GO:00703024 | Stomach | GC | regulation of stress-activated protein kinase signaling cascade | 26/1159 | 195/18723 | 1.81e-04 | 3.13e-03 | 26 |
GO:00310985 | Stomach | GC | stress-activated protein kinase signaling cascade | 30/1159 | 247/18723 | 3.20e-04 | 5.10e-03 | 30 |
GO:00514035 | Stomach | GC | stress-activated MAPK cascade | 29/1159 | 239/18723 | 4.06e-04 | 6.18e-03 | 29 |
GO:00328734 | Stomach | GC | negative regulation of stress-activated MAPK cascade | 10/1159 | 51/18723 | 9.90e-04 | 1.18e-02 | 10 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MECOM | SNV | Missense_Mutation | novel | c.64N>T | p.His22Tyr | p.H22Y | | protein_coding | tolerated_low_confidence(0.65) | unknown(0) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
MECOM | SNV | Missense_Mutation | novel | c.1054C>T | p.His352Tyr | p.H352Y | Q03112 | protein_coding | tolerated(0.08) | probably_damaging(0.994) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
MECOM | SNV | Missense_Mutation | rs762099223 | c.1694C>A | p.Ala565Asp | p.A565D | Q03112 | protein_coding | deleterious(0.02) | benign(0.229) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
MECOM | SNV | Missense_Mutation | novel | c.1511N>C | p.Gln504Pro | p.Q504P | Q03112 | protein_coding | tolerated(0.46) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MECOM | SNV | Missense_Mutation | rs748747672 | c.710N>T | p.Ser237Leu | p.S237L | Q03112 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MECOM | SNV | Missense_Mutation | novel | c.1412N>T | p.Glu471Val | p.E471V | Q03112 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
MECOM | SNV | Missense_Mutation | | c.784N>C | p.Tyr262His | p.Y262H | Q03112 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AR-A256-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
MECOM | SNV | Missense_Mutation | | c.295N>A | p.Pro99Thr | p.P99T | | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A18T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
MECOM | SNV | Missense_Mutation | rs149892422 | c.256N>T | p.Arg86Cys | p.R86C | Q03112 | protein_coding | deleterious(0) | possibly_damaging(0.897) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
MECOM | SNV | Missense_Mutation | | c.568N>A | p.Asp190Asn | p.D190N | Q03112 | protein_coding | tolerated(0.06) | possibly_damaging(0.787) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |